Metformina Vir

Metformin, the active ingredient in Metformina Vir, is a biguanide presented as an oral tablet for oral use. It is used to lower blood glucose levels in adults with type 2 diabetes and related metabolic conditions.

GNH USA supplies Metformina Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina Vir belongs to the biguanide class and is indicated for disorders of glucose metabolism.

- Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose output and increasing peripheral insulin sensitivity. - Prediabetes: helps lower fasting plasma glucose and delays progression to overt diabetes. - Polycystic ovary syndrome (off‑label): reduces insulin resistance and may improve menstrual regularity.

Metformina Vir may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhoea: watery stools occurring especially during treatment initiation. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight observed in some patients.

Serious or Rare Side Effects: - Lactic acidosis: a rare but potentially fatal accumulation of lactate, particularly in patients with renal impairment. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: abnormal liver function tests or hepatitis in susceptible individuals.

Metformina Vir requires careful monitoring and patient education to minimise risks.

- Renal function monitoring: assess creatinine clearance before initiation and periodically thereafter. - Hepatic disease caution: avoid use in patients with significant liver dysfunction. - Lactic acidosis risk: discontinue promptly if patients develop unexplained acidosis, hypoxia, or severe infection. - Pregnancy and breastfeeding: safety data are limited; use only if potential benefit justifies potential risk. - Alcohol consumption: advise patients to limit alcohol intake as it may increase lactic acidosis risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metformina Vir can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations, enhancing toxicity. - Alcohol: potentiates risk of lactic acidosis and hypoglycaemia.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemic symptoms, requiring closer glucose monitoring. - Diuretics (especially thiazides): can impair renal function and elevate metformin levels.